4101 - 4150 of 9038 Results
Title
Year
- NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson’s Disease: Study Design and Status Update (P3.8-035)2019RESTRICTEDTitle: NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson’s Disease: Study Design and Status Update (P3.8-035)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 92Issue #: 15_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.92.15_supplement.p3.8-035Citation Count: 2
- Fox Insight: a Large-Scale Web-Enabled Parkinson’s Disease Study (P4.007)2017RESTRICTEDTitle: Fox Insight: a Large-Scale Web-Enabled Parkinson’s Disease Study (P4.007)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 88Issue #: 16_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.88.16_supplement.p4.007Citation Count: 0
- Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4) (P1.013)2017RESTRICTEDTitle: Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4) (P1.013)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 88Issue #: 16_supplementStart Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.88.16_supplement.p1.013Citation Count: 0
-
OPENTitle: Abstract #81: Improving Neurostimulation Clinical Trial Design with Patient Experience DataJournal Name: Brain StimulationPublisher: Elsevier BVVol: 12Issue #: 2Start Page: e28End Page: e29Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.brs.2018.12.088Best OA location URL: https://doaj.org/article/33431349c85d454db7ad2af33222a015Citation Count: 0
- Announcing a New Continuing Medical Education Course2013RESTRICTEDTitle: Announcing a New Continuing Medical Education CourseJournal Name: Cognitive and Behavioral NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 26Issue #: 2Start Page: 56End Page: 58Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/wnn.0b013e31829af2fbCitation Count: 1
- P4‐308: CSF α‐synuclein, BETA‐AMYLOID 1–42 and tau proteins: Relationship to clinical parameters in early Parkinson's disease2012RESTRICTEDTitle: P4‐308: CSF α‐synuclein, BETA‐AMYLOID 1–42 and tau proteins: Relationship to clinical parameters in early Parkinson's diseaseJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 8Issue #: 4S_Part_21Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.jalz.2013.08.089Citation Count: 0
- Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart Review2018RESTRICTEDTitle: Pimavanserin for Psychotic Symptoms in People With Parkinsonism: A Second Chart ReviewJournal Name: Clinical NeuropharmacologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 41Issue #: 5Start Page: 156End Page: 159Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/wnf.0000000000000296Citation Count: 12
- Qualitative Imaging of Adeno-Associated Virus Serotype 2–Human Aromatic L-Amino Acid Decarboxylase Gene Therapy in a Phase I Study for the Treatment of Parkinson Disease2010RESTRICTEDTitle: Qualitative Imaging of Adeno-Associated Virus Serotype 2–Human Aromatic L-Amino Acid Decarboxylase Gene Therapy in a Phase I Study for the Treatment of Parkinson DiseaseJournal Name: NeurosurgeryPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 67Issue #: 5Start Page: 1377End Page: 1385Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1227/neu.0b013e3181f53a5cCitation Count: 71
-
OPENTitle: Beliefs About Use of Complementary Health Approaches for Parkinson's DiseaseJournal Name: Holistic Nursing PracticePublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 31Issue #: 5Start Page: 290End Page: 294Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1097/hnp.0000000000000229Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/5664950Citation Count: 0
-
OPENTitle: Paraquat Neurotoxicity is Distinct from that of MPTP and RotenoneJournal Name: Toxicological SciencesPublisher: Oxford University Press (OUP)Vol: 88Issue #: 1Start Page: 193End Page: 201Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1093/toxsci/kfi304Best OA location URL: https://academic.oup.com/toxsci/article-pdf/88/1/193/4676394/kfi304.pdfCitation Count: 269
-
OPENTitle: Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injuryJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 10Issue #: 1SStart Page: S62End Page: 75Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.jalz.2013.12.011Best OA location URL: http://doi.org/10.1016/j.jalz.2013.12.011Citation Count: 70
-
OPENTitle: fMRI-based deep brain stimulation programming for Parkinson's disease: a blinded, crossover clinical trialJournal Name: Brain StimulationPublisher: Elsevier BVVol: 19Issue #: 2Start Page: 103069End Page: 103069Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.brs.2026.103069Best OA location URL: https://www.brainstimjrnl.com/article/S1935-861X(26)00046-X/pdfCitation Count: 1
-
OPENTitle: Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 3Start Page: 672End Page: 680Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.28382Best OA location URL: https://doi.org/10.1002/mds.28382Citation Count: 23
-
OPENTitle: Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson’s DiseaseJournal Name: MDM Policy & PracticePublisher: SAGE PublicationsVol: 6Issue #: 1Start Page: 23814683211021380End Page: 23814683211021380Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1177/23814683211021380Best OA location URL: https://journals.sagepub.com/doi/pdf/10.1177/23814683211021380Citation Count: 14
-
OPENTitle: Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) DimerizationJournal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 14Issue #: 11Start Page: 1971End Page: 1980Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1021/acschemneuro.3c00259Best OA location URL: https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.3c00259Citation Count: 24
-
OPENTitle: Mitochondrial therapies for Parkinson's diseaseJournal Name: Movement DisordersPublisher: WileyVol: 25Issue #: S1Start Page: S155End Page: 60Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.22781Best OA location URL: http://doi.org/10.1002/mds.22781Citation Count: 62
- Dysphagia Is Associated with Incident Non‐Motor Symptoms in Parkinson's Disease2025RESTRICTEDTitle: Dysphagia Is Associated with Incident Non‐Motor Symptoms in Parkinson's DiseaseJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 12Issue #: 11Start Page: 1909End Page: 1924Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mdc3.70297Citation Count: 0
-
OPENTitle: PINK 1 autophosphorylation is required for ubiquitin recognitionJournal Name: The EMBO ReportsPublisher: Springer Science and Business Media LLCVol: 19Issue #: 4Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.15252/embr.201744981Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.15252/embr.201744981Citation Count: 117
- Dopaminergic dose adjustment and negative affective symptoms after deep brain stimulation2018RESTRICTEDTitle: Dopaminergic dose adjustment and negative affective symptoms after deep brain stimulationJournal Name: Journal of the Neurological SciencesPublisher: Elsevier BVVol: 390Issue #:Start Page: 33End Page: 35Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.jns.2018.04.002Citation Count: 2
- What Parkinson's disease patients say in their own words about their mood and anxiety symptoms2024RESTRICTEDTitle: What Parkinson's disease patients say in their own words about their mood and anxiety symptomsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 130Issue #:Start Page: 107190End Page: 107190Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2024.107190Citation Count: 3
-
OPENTitle: Efficacy of biologically-directed daylight therapy on sleep and circadian rhythm in Parkinson's disease: a randomised, double-blind, parallel-group, active-controlled, phase 2 clinical trialJournal Name: eClinicalMedicinePublisher: Elsevier BVVol: 69Issue #:Start Page: 102474End Page: 102474Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.eclinm.2024.102474Best OA location URL: http://www.thelancet.com/article/S2589537024000531/pdfCitation Count: 26
-
OPENTitle: Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson's disease and DLBJournal Name: Proceedings of the National Academy of SciencesPublisher: National Academy of SciencesVol: 115Issue #: 51Start Page: E12053End Page: E12062Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1073/pnas.1813365115Best OA location URL: https://www.pnas.org/content/pnas/115/51/E12053.full.pdfCitation Count: 92
-
OPENTitle: Minimal Clinically Important Difference for UPDRS‐III in Daily PracticeJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 5Issue #: 4Start Page: 448End Page: 450Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.12632Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.12632Citation Count: 63
-
OPENTitle: Dual role of USP 30 in controlling basal pexophagy and mitophagyJournal Name: The EMBO ReportsPublisher: Springer Science and Business Media LLCVol: 19Issue #: 7Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.15252/embr.201745595Best OA location URL: https://doi.org/10.15252/embr.201745595Citation Count: 163
- Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease2020RESTRICTEDTitle: Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 1Start Page: 178End Page: 187Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.28299Citation Count: 49
- Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia2013RESTRICTEDTitle: Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesiaJournal Name: Neuroscience ResearchPublisher: Elsevier BVVol: 77Issue #: 4Start Page: 242End Page: 246Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.neures.2013.10.002Citation Count: 47
-
OPENTitle: Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonismJournal Name: Movement DisordersPublisher: WileyVol: 33Issue #: 10Start Page: 1632End Page: 1642Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/mds.27404Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.27404Citation Count: 16
-
OPENTitle: Neuromodulation targets pathological not physiological beta bursts during gait in Parkinson's diseaseJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 120Issue #:Start Page: 107End Page: 117Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.nbd.2018.09.004Best OA location URL: https://doaj.org/article/2232316968e3403b8d7208ad3725eaf1Citation Count: 148
-
OPENTitle: Stimulation-induced reversed plus-minus syndrome: Insights into eyelid physiologyJournal Name: Brain StimulationPublisher: Elsevier BVVol: 11Issue #: 4Start Page: 951End Page: 952Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.brs.2018.04.010Best OA location URL: https://doaj.org/article/b711f7d9567240b89145b894bc21f1beCitation Count: 3
- Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia2016OPENTitle: Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasiaJournal Name: CortexPublisher: Elsevier BVVol: 83Issue #:Start Page: 124End Page: 135Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.cortex.2016.07.004Best OA location URL: https://doi.org/10.1016/j.cortex.2016.07.004Citation Count: 23
-
OPENTitle: Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: Evidence from Parkinson’s disease patients with defined cholinergic lossesJournal Name: NeuroImagePublisher: Elsevier BVVol: 149Issue #:Start Page: 295End Page: 304Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuroimage.2017.02.006Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/5386784Citation Count: 50
-
OPENTitle: Gut microbiome-derived tryptophan metabolites predict relapse in alcohol use disorderJournal Name: Brain, Behavior, and ImmunityPublisher: Elsevier BVVol: 131Issue #:Start Page: 106161End Page: 106161Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.bbi.2025.106161Best OA location URL: https://doi.org/10.1016/j.bbi.2025.106161Citation Count: 1
-
OPENTitle: Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson diseaseJournal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol: 2Issue #: 10Start Page: 949End Page: 959Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/acn3.246Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acn3.246Citation Count: 202
-
OPENTitle: A molecular glue for PRKN/parkinJournal Name: AutophagyPublisher: Informa UK LimitedVol: 21Issue #: 3Start Page: 689End Page: 690Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1080/15548627.2024.2443232Best OA location URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11849950/pdf/KAUP_21_2443232.pdfCitation Count: 2
-
OPENTitle: mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cellsJournal Name: Disease Models & MechanismsPublisher: The Company of BiologistsVol: 12Issue #: 10Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1242/dmm.038596Best OA location URL: https://doi.org/10.1242/dmm.038596Citation Count: 72
- Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats2016RESTRICTEDTitle: Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian ratsJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 110Issue #:Start Page: 125End Page: 134Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2016.07.025Citation Count: 29
-
OPENTitle: FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage diseaseJournal Name: NeuroImage: ClinicalPublisher: Elsevier BVVol: 20Issue #:Start Page: 572End Page: 579Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.nicl.2018.08.006Best OA location URL: https://doi.org/10.1016/j.nicl.2018.08.006Citation Count: 92
- Effects of augmenting cholinergic neurotransmission on balance in Parkinson's disease2019RESTRICTEDTitle: Effects of augmenting cholinergic neurotransmission on balance in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 69Issue #:Start Page: 40End Page: 47Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2019.10.022Citation Count: 27
-
OPENTitle: Magnetoelectric nanoparticle technology for mitigating motor deficits in Parkinsonian miceJournal Name: Brain StimulationPublisher: Elsevier BVVol: 18Issue #: 5Start Page: 1551End Page: 1560Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.brs.2025.08.008Best OA location URL: https://doi.org/10.1016/j.brs.2025.08.008Citation Count: 3
- Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study2018RESTRICTEDTitle: Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 18Issue #: 2Start Page: 165End Page: 176Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(18)30391-0Citation Count: 107
- Cough and Swallowing Therapy and Their Effects on Vocal Fold Bowing and Laryngeal Lesions2023RESTRICTEDTitle: Cough and Swallowing Therapy and Their Effects on Vocal Fold Bowing and Laryngeal LesionsJournal Name: The LaryngoscopePublisher: WileyVol: 134Issue #: 3Start Page: 1127End Page: 1132Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/lary.30922Citation Count: 6
- No evidence for toxicity after long-term photobiomodulation in normal non-human primates2017RESTRICTEDTitle: No evidence for toxicity after long-term photobiomodulation in normal non-human primatesJournal Name: Experimental Brain ResearchPublisher: Springer Science and Business Media LLCVol: 235Issue #: 10Start Page: 3081End Page: 3092Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s00221-017-5048-7Citation Count: 41
-
OPENTitle: Novel method to ascertain chromatin accessibility at specific genomic loci from frozen brain homogenates and laser capture microdissected defined cellsJournal Name: NeuroepigeneticsPublisher: Elsevier BVVol: 6Issue #:Start Page: 1End Page: 9Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.nepig.2016.03.001Best OA location URL: https://doi.org/10.1016/j.nepig.2016.03.001Citation Count: 0
-
OPENTitle: An ankyrin repeat chaperone targets toxic oligomers during amyloidogenesisJournal Name: Protein SciencePublisher: WileyVol: 32Issue #: 8Start Page: e4728End Page: e4728Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/pro.4728Best OA location URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10367600/pdf/PRO-32-e4728.pdfCitation Count: 2
-
OPENTitle: Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal systemJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 48Issue #: 1Start Page: 9End Page: 19Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.nbd.2012.06.005Best OA location URL: https://doaj.org/article/51752686f9774ce2aae93abfd8ee862eCitation Count: 81
- Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles2024OPENTitle: Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profilesJournal Name: eLifePublisher: eLife Sciences Publications, LtdVol: 13Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.7554/elife.92775.3Best OA location URL: https://doi.org/10.7554/elife.92775.3Citation Count: 13
- Fidelity of frequency and phase entrainment of circuit-level spike activity during DBS2015RESTRICTEDTitle: Fidelity of frequency and phase entrainment of circuit-level spike activity during DBSJournal Name: Journal of NeurophysiologyPublisher: American Physiological SocietyVol: 114Issue #: 2Start Page: 825End Page: 834Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1152/jn.00259.2015Citation Count: 48
-
OPENTitle: Influence of species and processing parameters on recovery and content of brain tissue‐derived extracellular vesiclesJournal Name: Journal of Extracellular VesiclesPublisher: WileyVol: 9Issue #: 1Start Page: 1785746End Page: 1785746Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1080/20013078.2020.1785746Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1080/20013078.2020.1785746Citation Count: 122
-
OPENTitle: Lack of epistatic interaction of SNCA with APOE in synucleinopathiesJournal Name: Brain CommunicationsPublisher: Oxford University Press (OUP)Vol: 7Issue #: 6Start Page: fcaf455End Page: fcaf455Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1093/braincomms/fcaf455Best OA location URL: https://doi.org/10.1093/braincomms/fcaf455Citation Count: 0
-
OPENTitle: Multimodal MRI evaluation of parkinsonian limbic pathologiesJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 76Issue #:Start Page: 194End Page: 200Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2019.01.004Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/6461740Citation Count: 15